Qu Biologics publishes potentially paradigm-shifting results of their first randomized-placebo controlled trial for the treatment of Crohn’s disease

NEXT STORY
Infection Control & Biosafety Products Market, 2018-2023 – In 2018, Combined Global Sales of Injection Devices Totaled $2.7Bn, with Safety Needles & Syringes Accounting for Nearly 90% of Sales
PREV STORY
World Specialty Endoscopic Surgery Devices Market Outlook to 2023 – Includes Medical Device Product Portfolios Offered by Leading Manufacturers & Procedure Volumes for Specialty Endoscopic Surgeries
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Valeo Pharma Announces $10 Million Bought Deal Private Placement of Convertible Debentures With Concurrent $10 Million Private Placement From Investissement Quebec

author_avatar
NASDAQ Market News

Biocartis Group NV: BIOCARTIS LAUNCHES EQUITY PLACEMENT

THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF ...

author_avatar
NASDAQ Market News

AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis

author_avatar
NASDAQ Market News